Prakt. lékáren. 2019; 15(2): 77-81 | DOI: 10.36290/lek.2019.039

Cardiovascular pharmacotherapy in childhood

Karel Koubský, Jan Janoušek, Václav Chaloupecký
Dětské kardiocentrum 2. lékařské fakulty Univerzity Karlovy a Fakultní nemocnice v Motole, Praha

The article summarises current medical treatment of heart failure, pulmonary hypertension and heart rhythm disorders in children.
Pharmacologic manipulation of the arterial duct in newborns with critical congenital heart defects is also addressed.

Keywords: heart failure, pulmonary hypertension, cardiac arrhythmia, congenital heart defect, ductus arteriosus

Received: January 26, 2019; Accepted: February 8, 2019; Published: June 20, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Koubský K, Janoušek J, Chaloupecký V. Cardiovascular pharmacotherapy in childhood. Praktické lékárenství. 2019;15(2):77-81. doi: 10.36290/lek.2019.039.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Chaloupecký V, Bartáková H, Belšan T, Hadačová I, Hroboňová V, Janoušek J, et al. Dětská kardiologie. Praha: Galén; 2006. 444 s.
    2. Kirk R, Dipchand A, Rosenthal D. ISHLT Guidelines for the Management of Pediatric Heart Failure. Kirklin JK, editor. Birmingham, AL, US: UAB Printing; 2014. 273 s.
    3. Lilleberg J, Laine M, Palkama T, Kivikko M, Pohjanjousi P, Kupari M. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Hear. Fail. 2007; 9(1): 75-82. Go to original source... Go to PubMed...
    4. Jain S, Vaidyanathan B. Digoxin in management of heart failure in children: Should it be continued or relegated to the history books? Ann. Pediatr. Cardiol. 2009 Jul; 2(2): 149-52. Go to original source... Go to PubMed...
    5. Hansmann G, Apitz C. Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart. 2016;102: ii67-ii85. Go to original source...
    6. Janoušek J, Andršová I, Bébarová M, Gebauer RA, Kubuš P, Novotný T, et al. EKG a dysrytmie v dětském věku. Praha: Grada; 2014. 276 s.
    7. Brugada J, Blom N, Sarquella-Brugada G, Blomstrom-Lundqvist C, Deanfield J, Janousek J, et al. Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement. Europace. 2013; 15(9): 1337-1382. Go to original source... Go to PubMed...
    8. Lieve KV, Wilde AA, van der Werf C. The Role of Flecainide in the Management of Catecholaminergic Polymorphic Ventricular Tachycardia. Arrhythmia Electrophysiol. Rev. 2016 May; 5(1): 45-49. Go to original source...
    9. Ackerman MJ, Priori SG, Dubin AM, Kowey P, Linker NJ, Slotwiner D, et al. Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent? Heart Rhythm. 2017 Jan; 14(1): e41-44. Go to original source... Go to PubMed...
    10. Coceani F. Therapeutic manipulation of the ductus arteriosus: current options and future prospects. Polish Arch. Intern. Med. 2014 Jan 15; 124(1-2): 58-64. Go to original source...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.